Abstracts tagged "Disease Activity"

Abstract Number: 1902 • 2014 ACR/ARHP Annual Meeting
Utility of Glyca, a Novel Inflammatory Marker, for Assessment of Rheumatoid Arthritis Disease Activity
Michelle Ormseth¹, Cecilia P. Chung², Joseph F. Solus³, Annette M. Oeser³, Margery A. Connelly⁴, Jim Otvos⁴ and C Michael Stein³, ¹Department of Medicine, Division of Rheumatology, Vanderbilt University, Nashville, TN, ²Medicine, Vanderbilt University, Nashville, TN, ³Vanderbilt University, Nashville, TN, ⁴LipoScience, Inc., Raleigh, NC
Background/Purpose GlycA is a novel inflammatory biomarker measured from the nuclear magnetic resonance (NMR) spectra obtained for lipoprotein particle analysis. It represents a distinct peak…
Abstract Number: 1386 • 2014 ACR/ARHP Annual Meeting
Disease Flares during 10 Year Follow-up in Patients with Rheumatoid Arthritis Are Associated with Joint Damage Progression and Disability
I.M. Markusse¹, L. Dirven², Y.P. Goekoop-Ruiterman³, P.a. van der Lubbe⁴, A.J. Peeters⁵, P.J.S.M. Kerstens⁶, W.F. Lems^7,8, T.W.J. Huizinga² and C.F. Allaart², ¹Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Rheumatology, HAGA hospital, The Hague, Netherlands, ⁴Rheumatology, Vlietland Hospital, Schiedam, Netherlands, ⁵Rheumatology, Reinier de Graaf Gasthuis, Delft, Netherlands, ⁶Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁷Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁸Rheumatology, VU Medical Center, Amsterdam, Netherlands
Background/Purpose: Disease flares frequently occur in patients with rheumatoid arthritis (RA). It has been suggested that these may spontaneously remit, in which case targeted treatment…
Abstract Number: 1039 • 2014 ACR/ARHP Annual Meeting
Interleukin-20 Is Triggered By TLR Ligands and Associates with Rheumatoid Arthritis Disease Activity
Ladislav Senolt¹, Klara Prajzlerova¹, Hana Hulejova², David Veigl³, Karel Pavelka¹ and Jiri Vencovsky¹, ¹Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ²Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, ³1st Orthopaedic Clinic, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent synovial inflammation and subsequent joint damage with systemic manifestations. Interleukin-20 (IL-20) has been…
Abstract Number: 666 • 2014 ACR/ARHP Annual Meeting
Approach to Discriminate Treatment Impact in Both Moderate and Severe SLE: The Atacicept Phase IIb Trial Design
Joan T. Merrill¹, Yong Li², Stephen D. Wax³ and Christopher Tehlirian⁴, ¹Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²R&D Global BioStatistics, EMD Serono, Billerica, MA, ³Global Clinical Development Center - Immunology, EMD Serono Inc, Rockland, MA, ⁴EMD Serono, Rockland, MA
Background/Purpose Increases in background treatment in SLE trials lead to high placebo group responses in patients with moderate but not those with high disease activity…
Abstract Number: 390 • 2014 ACR/ARHP Annual Meeting
Prevalence and Correlates of Patient-Physician Discordance in Early Rheumatoid Arthritis
John M. Davis III¹, Cynthia S. Crowson², Tim Bongartz¹, Clement J. Michet¹, Eric L. Matteson¹ and Sherine E. Gabriel³, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic, Rochester, MN, ³Health Sciences Research & Div of Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose Patients with rheumatoid arthritis (RA) sometimes rate their global disease activity differently than their rheumatologists. Previous studies describing this ‘discordance’ have primarily included patients…
Abstract Number: 101 • 2014 ACR/ARHP Annual Meeting
Country of Residence and Its Wealth Determine Disease Activity Levels in RA: Results from Multi-National Study Across 17 Countries (COMORA)
Polina Putrik^1,2, Sofia Ramiro³, Andras Keszei⁴, Ihsane Hmamouchi⁵, Maxime Dougados⁶, Till Uhlig⁷, Tore K. Kvien⁷ and Annelies Boonen⁸, ¹Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ²Health Promotion, Maastricht University, Maastricht, Netherlands, ³Rheumatology, Amsterdam Rheumatology Center, University of Amsterdam & Hospital Garcia de Orta, Almada, Portugal, Amsterdam, Netherlands, ⁴Medical Informatics, Uniklinik RWTH Aachen University, Aachen, Germany, ⁵Biostatistics, Epidemiology LBRCE, Mohamed V Souissi University, Rabat, Morocco, ⁶Cochin Hospital, Paris Descartes University, Paris, France, ⁷Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁸Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands
Background/Purpose Socio-economic (SE) inequalities in health persist both between and within countries and even increased in the recent years. Therefore, it is important to explore…
Abstract Number: 2989 • 2014 ACR/ARHP Annual Meeting
Lupus Impact Tracker Is Responsive to Changes in Disease Activity in Lupus
David Giangreco¹, Hervé Devilliers², Narender Annapureddy¹, Joel A. Block³ and Meenakshi Jolly¹, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Dijon University Hospital, Department of internal medicine and systemic diseases, Dijon, France, ³Section of Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Patient reported outcomes (PRO) are important to understand, educate, manage and follow patients with systemic lupus erythematosus (SLE). Lupus Impact Tracker (LIT) is a…
Abstract Number: 2619 • 2014 ACR/ARHP Annual Meeting
Low Socioeconomic Status (SES) As Measured By Education Is (not) Associated with Worse Outcome in SLE: Data from the 1000 Canadian Faces of Lupus
Angela George¹, Christine Peschken², Earl Silverman³, Christian A. Pineau⁴, C Douglas Smith⁵, Hector Arbillaga⁶, Michel Zummer⁷, Ann Clarke⁸, Sasha Bernatsky⁹, Marie Hudson¹⁰, Carol A. Hitchon¹¹, Paul R. Fortin¹² and Janet E. Pope¹³, ¹Medicine/Rheumatology, University of Western Ontario, London, ON, Canada, ²Medicine & Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada, ³Pediatrics/Rheumatology, Toronto Hospital for Sick Children, U of Toronto, Toronto, ON, Canada, ⁴Rheumatology, McGill University Health Center, Montreal, QC, Canada, ⁵The Arthritis Centre, TOH Riverside Campus, Ottawa, ON, Canada, ⁶Medicine/Rheumatology, Lethbridge Rheumatology practice, Lethbridge, AB, Canada, ⁷Medicine/Rheumatology, U of Montreal, Montreal, QC, Canada, ⁸Medicine/Allergy, U of Calgary, Calgary, AB, Canada, ⁹Clinical Epidemiology, McGill UHC/RVH, Montreal, QC, Canada, ¹⁰Medicine/Rheumatology, McGill University, Montreal, QC, Canada, ¹¹Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ¹²Rheumatology, Laval University, Division of Rheumatology, Centre de Recherche du CHU de Québec and Department of Medicine, Quebec City, QC, Canada, ¹³St Joseph Health Care, London, ON, Canada
Background/Purpose: To determine whether socioeconomic status, as measured by education, impacts disease activity (measured by SLAM-2, SLEDAI-2K) or disease damage (measured by SLICC SDI) in…
Abstract Number: 2404 • 2014 ACR/ARHP Annual Meeting
RA Patients with Inadequate Response to Oral MTX Maintain Satisfactory Disease Control and Durable Long-Term Response When Switched to SC MTX Monotherapy
Anthony Hammond¹ and Michael Batley², ¹Rheumatology, Maidstone and Tunbridge Wells NHS Trust, Kent TN13 2JD, United Kingdom, ²Rheumatology, Maidstone and Tunbridge Wells Hospital, Kent, United Kingdom
Background/Purpose: Methotrexate (MTX) is the cornerstone of rheumatoid arthritis (RA) therapy, but many patients do not achieve adequate response to oral therapy for reasons of…
Abstract Number: 1871 • 2014 ACR/ARHP Annual Meeting
Puberty and Disease Activity in JIA
Philomine A. van Pelt¹, Aike.a. Kruize², Anita C.S. Hokken-Koelega³, Radboud JEM Dolhain⁴, Johannes WJ Bijlsma⁵ and Nico M. Wulffraat⁶, ¹Rheumatology, Erasmus MC, Rotterdam, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Pediatrics, Subdivision of Endocrinology, Erasmus Medical Center- Sophia Children's Hospital, Rotterdam, Netherlands, ⁴Rheumatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands, ⁵Dept of Rheumatology and Immunology, University Medical Centre Utrecht, Utrecht, Netherlands, ⁶Paediatric Immunology, University Medical Centre Utrecht, Utrecht, Netherlands
Background/Purpose Delayed puberty and decreased final length has been reported in chronic diseases like Crohn's disease and JIA with a disease onset at prepubertal age.…
Abstract Number: 1375 • 2014 ACR/ARHP Annual Meeting
Educational Level and Not Ethnicity an Important Determinant of Disease Progression in Patients with Rheumatoid Arthritis
Sharon Dowell¹, Gail S. Kerr², Yusuf Yazici³, Christopher Swearingen⁴, Mercedes Quinones⁵, Luis R. Espinoza⁶, Edward L. Treadwell⁷, Theresa Lawrence-Ford⁸, Yvonne Sherrer⁹, Angelia Mosley-WIlliams¹⁰, Ignacio Garcia-Valladares¹¹, Rodolfo Perez Alamino¹², Chunqiao Luo¹³, Akgun Ince¹⁴, Adrian Godoy¹ and John Amatruda¹⁵, ¹Division of Rheumatology, Howard University, Washington, DC, ²Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC, ³Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁴Pediatrics and Biostatistics, University of Arkansas, Little Rock, AR, ⁵Division of Rheumatology, Howard University Hospital, Washington, DC, ⁶Medicine-Section of Rheum, LSU Medical Center, New Orleans, LA, ⁷Dept Medicine Div of Rheum, East Carolina University, Greenville, NC, ⁸North Georgia Rheumatology Group, PC, Lawrenceville, GA, ⁹Rheum/Immunology, Centre Rheum Immunol Arthritis, Fort Lauderdale, FL, ¹⁰Rheumatology, Detroit VAMC, Detroit, MI, ¹¹Immunology and Rheumatology, Hospital General de Occidente, Zapopan, Jal., Mexico, ¹²internal Medicine, LSUHSC, New Orleans, LA, ¹³University of Arkansas for Medical Sciences, Little Rock, AR, ¹⁴Arthitis Consultants Inc, St. Louis University, St. Louis, MO, ¹⁵Rheumatology, Howard University, Washington, DC
Background/Purpose: Formal educational level is often used as a surrogate for socioeconomic status and in patients with rheumatoid arthritis (RA), low levels have been associated…
Abstract Number: 1002 • 2014 ACR/ARHP Annual Meeting
Global Transcriptome Analysis in Osteoarthritic Cartilage Reveals Significant Differential Gene Expression and Associations with Histologic Disease Progression
Matlock A. Jeffries^1,2, Madison Donica³, Anand Annan⁴, Michael Stevenson⁵, Mary Beth Humphrey^6,7, Judith A. James^6,8 and Amr H. Sawalha⁹, ¹Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Arthritis & Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Pathol;ogy, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁶Rheumatology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁷Rheumatology/Immunology/Arthritis Section, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁸Clinical Arthritis and Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁹Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Osteoarthritis (OA) is the leading cause of chronic disability affecting 40% of individuals over the age of 70 and costing $128 billion annually in…
Abstract Number: 622 • 2014 ACR/ARHP Annual Meeting
Gut Microbiota Variations Correlate with Disease Activity in Spondyloarthritis (SpA) and Rheumatoid Arthritis (RA)
Julien Tap^1,2, Jad Abou-Ghantous¹, Ariane Leboime³, Roula Said Nahal³, Philippe Langella¹, Henri-Jean Garchon⁴, Gilles Chiocchia⁵, Jean-Pierre Furet¹ and Maxime Breban^3,4, ¹UMR INRA-AgroParisTech 1319, Equipe ProbiHote, MICALIS Institute, National Institute for Agronomical research (INRA), Jouy-en-Josas, France, ²Metagenopolis, INRA, Jouy-en-Josas, France, ³Service de Rhumatologie, Hopital Ambroise Pare, Boulogne-Billancourt, France, ⁴INSERM U987, Faculté des Sciences de la Santé Simone Veil, Montigny-le-Bretonneux, France, ⁵Versailles Saint Quentin en Yvelines University, INSERM U987, UFR des Sciences de la Santé, Montigny-le-Bretonneux, France
Background/Purpose Inflammatory bowel diseases (IBD) are associated with changes in microbiota which may be responsible for sustained gut inflammation and/or a consequence of it. Whether…
Abstract Number: 388 • 2014 ACR/ARHP Annual Meeting
Soluble TREM-1 Is a Biomarker of Anti-CCP-Positive, DMARD-Naive Early Rheumatoid Arthritis
Shachaf Ofer-Shiber¹, Elisheva Pokroy-Shapira², Yair Molad^3,4, Shirly Oren², Hagit Shay-Aharoni² and Ilan Babai⁵, ¹Department of Internal Medicine H, Rabin Medical Center, Beilinson Hospital and Sackler Faculty of Medicine, Tel Aviv University, Petach Tikva, Israel, ²Rheumatology Unit, Rabin Medical Center, Beilinson Hospital and Sackler Faculty of Medicine, Tel Aviv University, Petach Tikva, Israel, ³Rheumatology Unit, Rabin Medical Center, Beilinson Hospital and Sackler Faculty of Medicine, Tel Aviv University, Petah Teqva, Israel, ⁴Laboratory of Inflammation Research, Felsenstein Medical Research Center, Sackler Faculty of Medicine, Tel Aviv University, Petach Tikva, Israel, ⁵Laboratory of Clinical Immunology, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel
Background/Purpose : Triggering receptor expressed on myeloid cells-1 (TREM-1) is a cell-surface receptor, expressed mainly on monocytes and neutrophils and involved in amplification of the inflammatory…
Abstract Number: 107 • 2014 ACR/ARHP Annual Meeting
Use of Internet in Adolescents and Young Adults with JIA
Philomine A. van Pelt¹, Constance H.C. Drossaert², Radboud JEM Dolhain³, A.a. Kruize⁴, Jaap Huisman⁵ and Nico Wulffraat⁶, ¹Rheumatology, Erasmus MC, Rotterdam, Netherlands, ²Psychology, Health and Technology, University of Twente, Enschede, Netherlands, ³Rheumatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands, ⁴Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Pediatric Psychology, Wilhelmina's Children Hospital UMC Utrecht, Utrecht, Netherlands, ⁶Paediatric Immunology and Rheumatology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose Internet-use is increasing since it is an efficient way to find information. Information obtained via Health Related Internet (HRI) sites, or online peer support…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].